We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

33 hedge funds and large institutions have $4.47M invested in Aspire Biopharma Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

735% more capital invested

Capital invested by funds: $536K → $4.47M (+$3.94M)

3% less funds holding

Funds holding: 34 → 33 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
33
Holders Change
-1
Holders Change %
-2.94%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
2
Calls
$724K
Puts
–
Net Calls
+$724K
Net Calls Change
+$10K

Top Buyers

Rank Fund Capital Flow
1
CA
Crossingbridge Advisors
New York
+$6.12K

Top Sellers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
-$23.6K
2
CCM
Context Capital Management
California
-$5.27K
3
EFI
EHP Funds Inc
Canada
-$753
4
CS
Clear Street
New York
-$4
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
1
Barclays
United Kingdom
$3.94M – – –
AC
2
Athos Capital
Hong Kong
$241K – – –
HCM
3
Highbridge Capital Management
New York
$45K – – –
SCM
4
Saba Capital Management
New York
$36.8K – – –
LA
5
Linden Advisors
New York
$32.6K – – –
PC
6
Periscope Capital
Ontario, Canada
$30.6K -$23.6K -643,365 -44%
AA
7
AQR Arbitrage
Connecticut
$19.5K – – –
SC
8
Sculptor Capital
New York
$18.7K – – –
WAM
9
Wolverine Asset Management
Illinois
$18K – – –
Verition Fund Management
10
Verition Fund Management
Connecticut
$13K – – –
TCA
11
Taconic Capital Advisors
New York
$9.03K – – –
PAMP
12
Polar Asset Management Partners
Ontario, Canada
$6.22K – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$6.02K – – –
LP
14
LMR Partners
United Kingdom
$5.61K – – –
WA
15
Whitebox Advisors
Minnesota
$5.61K – – –
FSI
16
Flow State Investments
Illinois
$5.1K – – –
CSD
17
Clear Street Derivatives
New York
$4.76K – – –
Nomura Holdings
18
Nomura Holdings
Japan
$4.5K – – –
KL
19
KIM LLC
Kansas
$4.49K – – –
EAM
20
Exos Asset Management
New York
$4.11K – – –
CCM
21
CAAS Capital Management
New York
$3.37K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$3.01K – – –
CS
23
Clear Street
New York
$2.38K -$4 -100 -0.2%
Walleye Capital
24
Walleye Capital
New York
$2.09K – – –
ACM
25
Atalaya Capital Management
New York
$1.5K – – –
1
2

ASBPW Hedge Fund Activity: Q2 2024 in Review

33 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2024, worth a combined $4.47M — up 735% from $536K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ASBPW and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest buyer was Crossingbridge Advisors, opening a new position worth an estimated $6.12K. The largest seller was Periscope Capital, cutting an estimated $23.6K.

  • 33 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2024, down from 34 in Q1 2024.
  • Funds reported $4.47M of Aspire Biopharma Warrant stock for Q2 2024, up 735% quarter-over-quarter.
  • 1 fund opened new Aspire Biopharma Warrant positions in Q2 2024 and 2 closed out, a net change of -1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q2 2024 was Crossingbridge Advisors, an estimated $6.12K added.
  • The largest Aspire Biopharma Warrant seller in Q2 2024 was Periscope Capital, an estimated $23.6K sold.

Based on aggregated 13F filings for Q2 2024.